DDInter740 DDInter737
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially approved by the FDA in 2010. Fingolimod was also studied for the treatment of COVID-19, the disease caused by infection with the SARS-CoV-2 virus.[L12654,L12657]
Flecainide {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Fingolimod
Flecainide {u} (Compound) causes {v} (Side Effect) Cardiac arrest
Cardiac arrest {u} (Side Effect) is caused by {v} (Compound) Fingolimod
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Flecainide {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Olanzapine
Olanzapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fingolimod
Flecainide {u} (Compound) causes {v} (Side Effect) Cardiac arrest
Cardiac arrest {u} (Side Effect) is caused by {v} (Compound) Edrophonium
Edrophonium {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fingolimod
Flecainide {u} (Compound) causes {v} (Side Effect) Gastrointestinal disorder
Gastrointestinal disorder {u} (Side Effect) is caused by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fingolimod
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Fingolimod
Flecainide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Nilotinib
Nilotinib {u} may lead to a major life threatening interaction when taken with {v} Fingolimod
Flecainide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Sulfamethoxazole
Sulfamethoxazole {u} may cause a minor interaction that can limit clinical effects when taken with {v} Fingolimod
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} (Compound) causes {v} (Side Effect) Atrioventricular block
Atrioventricular block {u} (Side Effect) is caused by {v} (Compound) Fingolimod
Flecainide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fingolimod (Compound)
Flecainide (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Fingolimod (Compound)
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may lead to a major life threatening interaction when taken with Fingolimod
Flecainide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Olanzapine (Compound) and Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Flecainide (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Edrophonium (Compound) and Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Fingolimod
Flecainide (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Fingolimod
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fingolimod (Compound)
Flecainide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Nilotinib (Compound) and Nilotinib may lead to a major life threatening interaction when taken with Fingolimod
Flecainide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Sulfamethoxazole (Compound) and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Fingolimod
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine (Compound) causes Atrioventricular block (Side Effect) and Atrioventricular block (Side Effect) is caused by Fingolimod (Compound)